Ampio Pharmaceuticals Inc 's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ampio Pharmaceuticals Inc 's ROA in the fourth quarter of 2023?
Ampio Pharmaceuticals Inc recorded a cumulative net loss of $-9 million during 12 months ending in the fourth quarter of 2023, resulting in a negative return on assets (ROA) of -103.79%.

However, within the Healthcare sector 960 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2023 from 4830 to 5481.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter	(Dec 31 2022) IV. Quarter
Y / Y Total Assets Change	-57.79 %	-59.41 %	-66.38 %	-67.26 %	-71.13 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-9	-9	-14	-15	-16
Return On Assets (TTM)	-103.79 %	-85.59 %	-106.9 %	-83.43 %	-70.7 %
AMPE's Total Ranking	# 5481	# 4830	# 5051	# 5073	# 5735
Total Assets (TTM) in million	6	8	9	11	14
Seq. Total Assets Change	-24.98 %	-16.43 %	-14.77 %	-21 %	-27.87 %
Seq. Net Income Change	-	-	-	-	-

AMPE's 5 Years Annual ROA >> Back to AMPE Management Effectiveness >> Compare AMPE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 458
Sector	# 961
Overall	# 5361

Return On Assets Statistics
High	Average	Low
243.02 %	-75.44 %	-427.03 %
(Dec 31 2018)		(Dec 31 2017)

Financial Statements
Ampio Pharmaceuticals Inc 's Assets	$ 6 million	AMPE's Balance sheet
Ampio Pharmaceuticals Inc 's Income	$ -2 million	Quarterly AMPE's Income Statement
AMPE's Income by Division		See AMPE's Income by Division

Annual Return On Assets	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020	(Dec 31 2019) FY 2019
Y / Y Total Assets Change	-57.79 %	-65 %	69.7 %	63.4 %	-0.21 %
Total Assets in million	6	14	39	23	14
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-9	-16	-17	-16	-14
Annual Return On Assets	-150.49 %	-120.23 %	-43.98 %	-69.47 %	-97.35 %

AMPE's 5 Years Annual ROA >> Back to AMPE Management Effectiveness >> Compare AMPE ROA to its Competitors

More Return On Assets Ratios
AMPE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMPE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMPE's Competitors
Subscribers only: Roa for Ampio Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for AMPE's Customers

You may also want to know
AMPE's Roi	AMPE's Inventory Turnover Ratio	AMPE's Growth Rates	AMPE's Dividend Comparisons
	AMPE's Profitability Ratios	AMPE's Asset Turnover Ratio	AMPE's Dividend Growth
AMPE's Roe	AMPE's Valuation Ratios	AMPE's Financial Strength Ratios	AMPE's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.